Canada is getting ready to release a national framework for assessing biomarker testing in cancer care—and it matters more than most people realize.
Precision medicine has transformed how we understand and treat cancer, especially through biomarker testing. These tests can help determine which treatments work best for which patients, sparing people from unnecessary side effects and guiding them toward better outcomes. But here’s the catch: access to these tests still depends too much on where you live, who your oncologist is, or whether you even know to ask.
That’s why I tuned in closely to Canada’s Drug Agency (CDA) webinars over the past week. They’ve brought together patient voices, industry experts, and health policy leads to talk about the new draft “Consensus Framework” being developed. This is a tool intended to guide how provinces evaluate, fund, and implement biomarker testing in cancer care.
Here’s what you need to know—and why The Heather Cutler Foundation is stepping in to help shape what happens next.
What’s Happening?
A time-limited advisory panel—made up of clinicians, policymakers, and two patient representatives—has been working since February 2025 to create this national framework. The goal is to finalize it by fall 2025.
As Robbie Spring, a cancer survivor and advisory panel member, put it during the webinar:
“We’ve seen promising tests and targeted treatments emerge—but no consistent process to evaluate them together. That’s a gap. And from where I sit, it’s a gap that hits patients the hardest.”
This framework won’t dictate how tests are performed or where they happen. Instead, it’s meant to help provinces evaluate which biomarkers to fund, and why. It includes both new and existing tests—everything from tumour mutation burden (TMB) to microsatellite instability (MSI), including hereditary genetic markers.
Why This Matters
Canada is playing catch-up. The science has moved ahead, but our systems haven’t.
Reports like Progress toward Health System Readiness for Genome-Based Testing in Canada and A State of Readiness Progress Report make it painfully clear: while provinces like Alberta and Quebec have made strides, others—especially smaller provinces and territories—still lack clear evaluation processes, funding models, or data integration systems.
That means people in Newfoundland, rural Manitoba, or the Maritimes may be missing out on life-extending treatment options—not because the science isn’t there, but because the infrastructure isn’t.
This framework is a chance to fix that. Or at least start.
Our Role and Our Plan
The Heather Cutler Foundation will be submitting official feedback on this draft framework when the public engagement process opens this summer (expected July 2025). If you want your voice included, we invite you to share your thoughts with us.
We’ve also requested that CDA host an additional webinar after the draft framework is completed. Patients, especially those in smaller provinces, deserve to understand what’s coming—and to shape it.
We’ll continue tracking this process and provide updates on how the framework evolves.
TL;DR – Key Takeaways
- What it is: A national framework to help provinces assess and fund biomarker testing in cancer.
- Why it matters: It aims to reduce care inequality across Canada and speed up access to personalized treatments.
- What’s next: A draft will be released for public feedback this July. Final version expected by September.
- How we’re involved: We’re preparing feedback, inviting public input, and pushing for more transparency through a post-release webinar.
If you’re a Canadian with cancer or love someone who is, this affects you. Precision medicine is no longer optional—it’s the standard of care. But unless our systems evolve, it will remain a privilege for a few instead of a right for all.
Let’s change that.
— Christopher Cutler, Founder, The Heather Cutler Foundation
